Literature DB >> 10982225

Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.

R Asero1.   

Abstract

BACKGROUND: About 30% of patients with chronic urticaria experience flares of hives and/or angioedema after ingesting either aspirin or nonsteroidal anti-inflammatory drugs. In such patients, cross-reactivity to all NSAIDs seems to occur suggesting a mechanism dependent on cyclooxygenase inhibition.
OBJECTIVE: To evaluate the preventive effect of leukotriene receptor antagonists on urticaria exacerbations induced by NSAIDs in a patient with chronic urticaria.
METHODS: A 59-year-old woman with a 2-year history of recurrent urticaria exacerbated by different NSAIDs including aspirin 500 mg (2 episodes), piroxicam 20 mg, and nimesulide 100 mg (1 episode each) was studied. Acetaminophen 375 mg and floctafenine 50 mg induced a marked flare of urticaria/angioedema in a single-blind, placebo-controlled challenge.
RESULTS: The patient was totally urticaria free during a 3-week course of montelukast 10 mg once a day. After montelukast withdrawal, a gradual relapse of urticaria/angioedema occurred along with a further acute urticaria/angioedema episode after a single piroxicam, 20-mg tablet. Zafirlukast 20 mg twice daily was started. After some days the patient was urticaria-free again, and after 3 weeks she tolerated a 6-day course of injective piroxicam (20 mg once a day) without any problem. To date the patient is still urticaria-free.
CONCLUSION: Leukotriene receptor antagonists may prevent the severe urticaria/angioedema exacerbations which follow the use of NSAIDs in some patients with chronic urticaria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982225     DOI: 10.1016/S1081-1206(10)62457-X

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  8 in total

Review 1.  Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs.

Authors:  Mario Sánchez-Borges; Arnaldo Capriles-Hulett; Fernan Caballero-Fonseca
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 2.  Evaluating chronic urticaria patients for allergies, infections, or autoimmune disorders.

Authors:  Y C Wai; Gordon L Sussman
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

3.  Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update.

Authors:  Riccardo Asero
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

Review 4.  The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.

Authors:  Eustachio Nettis; Maddalena D'Erasmo; Elisabetta Di Leo; Gianfranco Calogiuri; Vincenzo Montinaro; Antonio Ferrannini; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2010-09-22       Impact factor: 4.711

Review 5.  Drug-induced angioedema without urticaria.

Authors:  A Agostoni; M Cicardi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

6.  Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review.

Authors:  Gabriele Di Lorenzo; Alberto D'Alcamo; Manfredi Rizzo; Maria Stefania Leto-Barone; Claudia Lo Bianco; Vito Ditta; Donatella Politi; Francesco Castello; Ilenia Pepe; Gaetana Di Fede; Giovambattista Rini
Journal:  J Asthma Allergy       Date:  2008-12-09

7.  Chronic urticaria and drug hypersensitivity in children.

Authors:  Carlo Mastrorilli; Roberto Bernardini; Lucia Liotti; Fabrizio Franceschini; Giuseppe Crisafulli; Silvia Caimmi; Paolo Bottau; Francesca Mori; Fabio Cardinale; Francesca Saretta; Giovanni Simeone; Marcello Bergamini; Carlo Caffarelli
Journal:  Acta Biomed       Date:  2019-01-29

8.  Leukotriene Antagonists in Dermatology.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.